$232 Million

Shattuck Labs

Initial Public Offering

Bookrunner, October 2020

Shattuck Labs, Inc. is an innovative, clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as a new class of biologic medicine. Compounds derived from the Company’s proprietary Agonist Redirected Checkpoint (ARC) platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules in a single therapeutic. The Company’s lead, wholly owned product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPα checkpoint interaction to restore an anti-tumor immune response, and to activate the CD40 costimulatory receptor to bolster the immune response.

More Like This

Oct 2020
$219 Million

Initial Public Offering

Lead Left Bookrunner

View Details
Oct 2020
$104 Million

Initial Public Offering

Lead Left Bookrunner

View Details
Oct 2020
$288 Million

Initial Public Offering

Bookrunner

View Details